Compare BioNTech SE - ADR (BNTX) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Tyson Foods, Inc. — how do they compare? BioNTech SE - ADR trades at $93.46 (market cap $23.31B), while Tyson Foods, Inc. trades at $56 (market cap $19.85B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.62% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | TSN | |
|---|---|---|
Market Cap | $23.31B | $19.85B |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $68.75 |
52-Week Low | $83.89 | $50.72 |
Enterprise Value | $6.60B | $27.12B |
Dividend Yield | — | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Tyson Foods (TSN) trades at $55.85, down 2.29% today, reflecting bearish technical signals and mixed fundamentals. Recent Q3 2026 earnings of $0.99 per share beat estimates, but revenue missed expectations amid declining volumes. The company faces headwinds from persistent losses in its beef segment, though chicken and prepared foods remain profitable. Analyst consensus is a 'Buy' with a $68.50 price target, suggesting significant upside potential from current levels.
The outlook hinges on Tyson's ability to stabilize beef margins while leveraging strength in other segments. Investment appeal lies in its low P/S ratio of 0.36 and dividend yield, but risks include volatile commodity costs and execution challenges. Near-term performance will depend on Q3 2026 results and management's guidance update.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
